Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while iShares 7-10 Year Treasury Bond ETF trades at $90.15 (market cap $41.26B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 14.4× Dyne Therapeutics Inc. Common Stock's market cap, and iShares 7-10 Year Treasury Bond ETF is more actively traded (12,778,487 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| DYN | IEF | |
|---|---|---|
Market Cap | $2.86B | $41.26B |
Volume | 3,341,579 | 12,778,487 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $97.99 |
52-Week Low | $14.60 | $88.92 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IEF trades at $89.71, up 0.31% with a bearish technical signal from moving averages and oscillators. The ETF shows flat support/resistance around $89-90. Recent dividend payments of $0.31-$0.33 provide income, but financial ratios are unavailable. Market sentiment reflects Treasury volatility amid rising yields and inflation concerns.
Outlook remains cautious due to persistent bond market pressures and macroeconomic uncertainty. Opportunities exist for income-focused investors via dividends, but risks include prolonged yield increases and geopolitical factors affecting fixed income. Monitor Federal Reserve policy shifts for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
